FDA agrees to review Moderna’s mRNA flu vaccine application in a reversal

CNBC Published Updated Stocks
Sign in to save

Why it matters

The FDA has agreed to review Moderna's mRNA flu vaccine application, paving the way for its potential approval and availability for the upcoming influenza season.

Article tone

Neutral How the article is written, as reported by the source.

Expected market reaction

Bullish Confidence 90% How confidence is read Horizon: Short term Impact: Moderate

Market impact analysis based on bullish sentiment with 90% confidence.

Evidence trail

Evidence
Source CNBC
Claim FDA agrees to review Moderna’s mRNA flu vaccine application in a reversal
AI inference Bullish · 90%
Generated 2026-02-18 16:17

AI provenance

Analysed by Llama 3.1 8B Instant (Groq) Methodology v1.0 Generated
Technical identifiers
Provider tag
groq-llama-3.1-8b-instant
Analysis version
groq-llama-3.1-8b-instant
Article id
47188

Original source

The FDA is slated to make a decision on the flu shot on Aug. 5, which will allow Moderna to make the vaccine available for the upcoming influenza season.

Read the full article on CNBC

Original article published by CNBC on February 18, 2026. Analysis and insights provided by AnalystMarkets AI.

Related coverage